Telomir Pharmaceuticals, Inc. is a pre-clinical-stage pharmaceutical company focused on the development and commercialization of TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic treatment for human stem cells. Its goal is to develop and commercialize new t... Telomir Pharmaceuticals, Inc. is a pre-clinical-stage pharmaceutical company focused on the development and commercialization of TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic treatment for human stem cells. Its goal is to develop and commercialize new treatment options for age-related inflammatory conditions, with hemochromatosis as its initial clinical focus, and to thereafter expand the development of TELOMIR-1 to post-chemotherapy recovery as well as a broader range of other age-related inflammatory diseases and conditions such as osteoarthritis. 詳細を表示
Telomir Board of Directors appoints Erez Aminov as CEO and Chairman of the Board Telomir also announces Board of Directors departures and additions TAMPA, Fla., Aug. 12, 2024 (GLOBE NEWSWIRE...
TAMPA, Fla., July 02, 2024 (GLOBE NEWSWIRE) -- Telomir Pharmaceuticals, Inc. (Nasdaq: TELO) (“Telomir” or the “Company”), a pre-clinical-stage pharmaceutical company focused on the development...
期間 † | 前日比 | 前日比 % | 始値 | 高値 | 安値 | 平均出来高 | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.75 | 15.9914712154 | 4.69 | 5.44 | 4.35 | 288979 | 4.92251748 | CS |
4 | 0.54 | 11.0204081633 | 4.9 | 7.0791 | 3.86 | 260415 | 5.00551241 | CS |
12 | -0.99 | -15.3965785381 | 6.43 | 7.0791 | 3.198 | 136404 | 4.88860691 | CS |
26 | 0.01 | 0.184162062615 | 5.43 | 8.4 | 3.11 | 124933 | 5.44951091 | CS |
52 | -1.56 | -22.2857142857 | 7 | 20.72 | 3.11 | 95797 | 5.99227296 | CS |
156 | -1.56 | -22.2857142857 | 7 | 20.72 | 3.11 | 95797 | 5.99227296 | CS |
260 | -1.56 | -22.2857142857 | 7 | 20.72 | 3.11 | 95797 | 5.99227296 | CS |
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約